Today at 1:30 PM ET: Talking DTC with Olivier Chateau, CEO of Health Union, on patient communities, personalization, and rethinking rare disease marketing. There’s still time to register! dtcperspectives.zoom.us/webi…

Diagnosis is only the first hurdle. Payer barriers, pricing, and patient support all shape access in rare disease. Bob Ehrlich and Health Union CEO, Olivier Chateau discuss on this week's Talking DTC. Tue, Oct 20 | 1:30 PM ET Register free: dtcperspectives.zoom.us/webi…

How do rare disease patients find content that fits where they are in their journey? Olivier Chateau, CEO of Health Union, joins Bob Ehrlich to talk AI, earning patient trust, and personalization built on consent. 🗓️ Oct 20 | 1:30 PM ET Register: dtcperspectives.zoom.us/webi…

Rare disease patients are small in number and highly informed. Mass-market tactics don’t work for them. Join Bob Ehrlich and Health Union’s Olivier Chateau on Oct 20 at 1:30 PM ET to talk trust, lived experience, AI and access. Register free: dtcperspectives.zoom.us/webi…

What does it take to connect with patients when every individual matters? Bob Ehrlich sits down with Olivier Chateau, CEO of Health Union, to talk patient communities and the new path for rare disease marketing. 🗓️ Tue, Oct 20 | 1:30 PM ET Register: dtcperspectives.zoom.us/webi…

Rare disease marketing needs its own commercial playbook. Join Health Union and senior biopharma leaders 11/5 in Boston for the Rare Marketing Summit: practical strategy and candid peer exchange. Request an invitation: go.dtcperspectives.com/rare-… #RareDisease #PharmaMarketing

What does it actually take for a patient to trust a brand with their story? @SnowCompanies breaks down why real engagement, not transactional campaigns, is what builds lasting patient trust in pharma marketing. Read more: dtcperspectives.com/how-to-b…

FDA warning letters went from 5 in 2024 to 100+ within weeks. OPDP scrutiny now covers influencer content, patient testimonials, and HCP sites. @SnowCompanies shares what DTC marketers need to know about the new compliance reality. Read: dtcperspectives.com/rethinki…

Starting today at 1:30 PM ET: Our CEO, Bob Ehrlich, on the FDA's adequate provision proposal & what it means for DTC advertising. Join now (free): events.zoom.us/ev/At7qYPV-YV…

Tomorrow: Join our CEO, Bob Ehrlich, discussing the FDA's proposal to rescind adequate provision, and what it means for DTC advertising. 🗓️ Wed, Aug 19 | 1:30 PM ET Register now: events.zoom.us/ev/At7qYPV-YV…

Full package insert on a 60-second TV ad? That's the scenario if the FDA's adequate provision proposal moves forward. Bob Ehrlich covers the First Amendment angle, the legal fight ahead, and what marketers should do next. 🗓️ Wed, Aug 19 | 1:30 PM ET events.zoom.us/ev/At7qYPV-YV…

The FDA wants to rescind the rule that's made TV drug ads possible for ~30 years. Our CEO, Bob Ehrlich, breaks down what's next, and what it means for DTC advertising, in a free webinar. 🗓️ Wed, Aug 19 | 1:30 PM ET Register: events.zoom.us/ev/At7qYPV-YV…

The FDA just took aim at the adequate provision rule which allows for alternative means of risk disclosure. End it = no more branded TV ads as we know them. Survives court? Unlikely. Should DTC marketers still be worried about this threat? Yes. More: dtcperspectives.com/tv-ad-ba…

Final day of #DTCNational Big theme: everything is changing—fast. Media. Regulation. AI. Strategy. The brands that adapt fastest win. Don’t miss next year! #PharmaMarketing #FutureOfDTC

Day 2 at #DTCNational Deeper pharma insights. Bigger conversations. Tonight: Top Marketers + Hall of Fame 🏆 Presented by @patientpoint See the DTC pharma case studies presented today: eventcombo.com/ms/ev/76887/d… #PharmaMarketing #DTC

The DTC National starts today in Boston! Pharma leaders. Real case studies. FDA perspective. And tonight: Ad Awards + Agency Vanguard Awards. This is where DTC moves forward. Join us: eventcombo.com/ms/ev/76887/d… #DTCNational #PharmaMarketing

FDA Commissioner Marty Makary is coming to the 26th #DTCNational. Don't miss this rare, candid fireside chat on the future of DTC pharmaceutical and medical device advertising. 📅 April 21 📍 Boston Learn more: myemail.constantcontact.com/… #DTCPharma #DTC

DTC media is facing a reset. Regulation. Scrutiny. Changing expectations. What happens next? Join the debate at #DTCNational: Navigating the New Rules of Engagement with Olivier Chateau, CEO, Health Union More: myemail.constantcontact.com/… #DTCNational #PharmaMarketing

FDA scrutiny on DTC is rising fast. Untitled letters. New standards. Big questions about TV advertising. Now, the FDA is coming to the 2026 #DTCNational to speak directly with the industry. What happens next will shape everything. Read the breakdown: myemail.constantcontact.com/…

Bayer, S50 and BGB reveal how patient insight, connection, and leadership enabled a bold prostate cancer campaign. See "Patients Aren’t Just Your Audience—They’re Your Story: NUBEQA’s New Campaign Is Breaking Oncology Marketing Norms" at #DTCNational. myemail.constantcontact.com/…